<DOC>
	<DOCNO>NCT02110355</DOCNO>
	<brief_summary>Phase 1b/2a , open-label , sequential dose escalation expansion study AMG 232 combination trametinib dabrafenib subject metastatic melanoma follow direct comparison AMG 232 combine trametinib dabrafenib versus trametinib combine dabrafenib alone .</brief_summary>
	<brief_title>A Phase 1b/2a Study Evaluating AMG 232 Metastatic Melanoma</brief_title>
	<detailed_description>The study conduct 3 part : Part 1 - Dose Escalation , Part 2 - Dose Expansion Part 3 , randomize Phase 2a . In part 1 2 , subject enrol open-label 1 2 arm . For Arm 1 Arm 2 , part 1 dose escalation aim determine AMG 232 maximum tolerate dose ( MTD ) fix dose combination drug ( ) evaluate safety , tolerability , pharmacokinetics pharmacodynamics combination . Part 2 dose expansion enroll subject receive therapy dose schedule AMG 232 select correspond part 1 dose escalation . In part 2 subject enrol confirm safety tolerability assess clinical activity prior proceed Part 3 , Phase 2a . In Phase 2a , Subjects randomize open-label 1:1 ratio receive AMG 232 combination trametinib plus dabrafenib versus trametinib plus dabrafenib alone .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Subjects must histologically cytologically confirm metastatic cutaneous mucosal melanoma , Able swallow retain orally administer medication , Adequate hematological , renal , hepatic , coagulation laboratory assessment Clinically significant bleeding within 4 week screen , Current use warfarin , factor Xa inhibitor , direct thrombin inhibitor , Infection require antiinfective treatment within 1 week study enrollment , Antitumor therapy , Major surgery within 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic melanoma</keyword>
</DOC>